Loading
A phase 1 trial of DNX-2401 run by DNAtrix, Inc., completed.
DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas is a phase 1 interventional study registered as NCT00805376 by DNAtrix, Inc., with 37 participants enrolled, started 2009-02. Conditions recorded: Brain Cancer and Central Nervous System Diseases. Interventions recorded: DNX-2401 and Tumor Removal.
Shares DNX-2401, DNAtrix, Brain and spinal cord tumours (all types) and the tag pipeline.
Shares DNX-2401, DNAtrix, Brain and spinal cord tumours (all types) and the tag pipeline.
Shares DNX-2401, DNAtrix, Brain and spinal cord tumours (all types) and the tag pipeline.
Shares DNX-2401, DNAtrix, Brain and spinal cord tumours (all types) and the tag pipeline.
Shares DNX-2401, DNAtrix, Brain and spinal cord tumours (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/